NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.
You may also be interested in...
Zelboraf And Yervoy Benefit From Secret Discounts To Pass NICE Barrier
NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.
Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.
Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs
Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.